GAMIFANT 100 mg/20mL
emapalumab-lzsg · INJECTION · Swedish Orphan Biovitrum AB (publ)
Gamifant is an injection given intravenously to treat a serious immune condition called primary hemophagocytic lymphohistiocytosis by blocking interferon gamma, a protein that causes excessive inflammation. It is used in patients who cannot be treated with standard therapy or whose condition is not responding to standard treatment.
Key Facts
- Brand Name
- GAMIFANT
- Generic Name
- emapalumab-lzsg
- NDC Code (Product)
66658-510- Manufacturer
- Swedish Orphan Biovitrum AB (publ)
- Strength
- 100 mg/20mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761107
- Drug Class
- Interferon gamma Blocker [EPC]
- Marketing Start
- 06/26/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is GAMIFANT used for?
Gamifant is an injection given intravenously to treat a serious immune condition called primary hemophagocytic lymphohistiocytosis by blocking interferon gamma, a protein that causes excessive inflammation. It is used in patients who cannot be treated with standard therapy or whose condition is not responding to standard treatment.
Is GAMIFANT a controlled substance?
GAMIFANT is not classified as a controlled substance by the DEA.
What is the generic name for GAMIFANT?
The generic name for GAMIFANT is emapalumab-lzsg. There are no other listed brand versions of emapalumab-lzsg.
What is the NDC code for GAMIFANT 100 mg/20mL?
The NDC (National Drug Code) for GAMIFANT 100 mg/20mL is 66658-510, listed by Swedish Orphan Biovitrum AB (publ).
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)